Innovative startups could be prime acquisition targets for tech giants looking to capitalize on this world-changing application.
Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback